AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$ALEC

Rosenthal Arnon sold $193K of ALEC

Rosenthal Arnon (Chief Executive Officer) sold 72,606 shares of Alector, Inc. (ALEC) at $2.66 ($0.19M total) on 2026-09-03.

Original reporting
SEC EDGAR · Rosenthal Arnon
Published Sep 4, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALEC
Bearish
medium confidence
Mentioned
$ALEC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALECBearishLow
01

Why it matters

A modest insider sell may cause short-term price softness but is unlikely to drive major moves.

02

Market read

Provides fresh data for traders monitoring insider activity; may influence short-term trading decisions.

03

What to watch

Arnon's holdings remain large (over 2.2 million shares), indicating continued commitment.

Relevance 4/10Novelty 4/10Timing: post-market filing on 2026-09-04

Background

Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$ALECBearishMedium confidence
Context

CEO Rosenthal Arnon sold 72,606 shares for $193,473, reducing his stake.

Expected impact

Modest downside pressure in the near term.

Evidence & confidence

A $193k sale by the CEO is modest but notable; markets often react negatively to insider sells.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are common and not sector-wide.

Regional

No significant regional effect.

Global

Limited to investors tracking Alector.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a lack of confidence.

Key entities

  • Company
    Alector, Inc.

    Biotech firm listed on NASDAQ under ticker ALEC.

  • Person
    Rosenthal Arnon

    Chief Executive Officer of Alector.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALEC insider trading history →

Related articles

OCT 7
MedAI 8/10

Genentech pays Alector $100m for Parkinson drug

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.

bioxconomy.com2 min
OCT 6
HighAI 9/10

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.

ksl.com2 min
OCT 5
$ALECHigh

Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for A

Alector Inc (ALEC) shares rose 22% after announcing a licensing deal with Genentech for its AL050 program. The deal includes a $100M upfront payment and potential milestone payments up to $1.17B. Alector's P/S ratio is 17.46, higher than historical and industry averages, reflecting growth expectations. The company's GF Score is 31/100, indicating weak fundamentals but some momentum.

gurufocus.com2 min